Exploring market-approved azoles as potential breast cancer therapeutics targeting the VEGFR-2 biotarget.
Atta AM, Nafie MS, Ali HA, Saleh HK, Roshdy MA, Mahmoud MM, Eid EA, Ahmed MA, Gerges MS, Ghoneim AM, Refaie AH, Attia EE, Algandaby MM, Darwish KM.
Atta AM, et al.
Sci Rep. 2025 Dec 10;15(1):43581. doi: 10.1038/s41598-025-29322-6.
Sci Rep. 2025.
PMID: 41372291
Free PMC article.